Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 9000 results

  1. Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Aflibercept for untreated diabetic macular oedema [TSID10621]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Nitisinone for treating alkaptonuria [ID2691]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]

    Awaiting development Reference number: GID-TA11821 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]

    Awaiting development Reference number: GID-TA11583 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development Reference number: GID-TA11040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]

    Awaiting development Reference number: GID-TA11111 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]

    Awaiting development Reference number: GID-TA11393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development Reference number: GID-TA11326 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development